Wellington Management Group LLP Takes $1.16 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Wellington Management Group LLP bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 84,506 shares of the company’s stock, valued at approximately $1,159,000. Wellington Management Group LLP owned 0.19% of Vera Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Amalgamated Bank grew its stake in shares of Vera Therapeutics by 26.0% in the 3rd quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock worth $57,000 after purchasing an additional 864 shares during the last quarter. American International Group Inc. boosted its holdings in Vera Therapeutics by 29.2% during the first quarter. American International Group Inc. now owns 6,794 shares of the company’s stock worth $160,000 after buying an additional 1,535 shares in the last quarter. Royal Bank of Canada grew its position in Vera Therapeutics by 94.8% in the second quarter. Royal Bank of Canada now owns 3,339 shares of the company’s stock worth $54,000 after buying an additional 1,625 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Vera Therapeutics by 163.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company’s stock valued at $45,000 after buying an additional 1,731 shares in the last quarter. Finally, UBS Group AG acquired a new stake in shares of Vera Therapeutics during the first quarter worth $47,000. 99.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on VERA. Wedbush increased their price target on Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a research report on Thursday, March 21st. Oppenheimer started coverage on shares of Vera Therapeutics in a report on Thursday, January 25th. They set an “outperform” rating and a $26.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $25.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, November 30th. Guggenheim boosted their target price on shares of Vera Therapeutics from $27.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Raymond James upgraded Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $29.00 to $37.00 in a report on Friday, January 26th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Vera Therapeutics presently has an average rating of “Buy” and a consensus price target of $32.29.

Insider Transactions at Vera Therapeutics

In related news, Director Maha Katabi sold 340,000 shares of Vera Therapeutics stock in a transaction on Monday, March 25th. The stock was sold at an average price of $40.50, for a total transaction of $13,770,000.00. Following the completion of the sale, the director now owns 2,793,987 shares of the company’s stock, valued at $113,156,473.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Maha Katabi sold 340,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $40.50, for a total transaction of $13,770,000.00. Following the transaction, the director now owns 2,793,987 shares of the company’s stock, valued at $113,156,473.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Commodore Capital Lp sold 1,050,000 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $18.00, for a total transaction of $18,900,000.00. Following the completion of the sale, the insider now owns 4,400,000 shares of the company’s stock, valued at $79,200,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,471,009 shares of company stock valued at $36,250,598. 22.60% of the stock is owned by insiders.

Vera Therapeutics Stock Down 1.6 %

VERA stock opened at $43.12 on Friday. The company has a 50 day moving average of $40.32 and a two-hundred day moving average of $23.07. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -18.83 and a beta of 1.10. Vera Therapeutics, Inc. has a 12-month low of $5.95 and a 12-month high of $50.78. The company has a quick ratio of 6.97, a current ratio of 6.97 and a debt-to-equity ratio of 0.20.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.